Literature DB >> 15258796

Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis.

Yasunori Oka, Takashi Kanbayashi, Takahiro Mezaki, Kazumi Iseki, Jun Matsubayashi, Gaku Murakami, Masaru Matsui, Tetsuo Shimizu, Hiroshi Shibasaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15258796     DOI： 10.1007/s00415-004-0442-z

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  11 in total

1.  CSF hypocretin/orexin levels in narcolepsy and other neurological conditions.

Authors:  B Ripley; S Overeem; N Fujiki; S Nevsimalova; M Uchino; J Yesavage; D Di Monte; K Dohi; A Melberg; G J Lammers; Y Nishida; F W Roelandse; M Hungs; E Mignot; S Nishino
Journal:  Neurology       Date:  2001-12-26       Impact factor: 9.910

2.  Hypocretin (orexin) deficiency in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

3.  Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; S Nevsimalova; G J Lammers; J Vankova; M Okun; W Rogers; S Brooks; E Mignot
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

4.  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.

Authors:  Emmanuel Mignot; Gert Jan Lammers; Beth Ripley; Michele Okun; Sonia Nevsimalova; Sebastiaan Overeem; Jitka Vankova; Jed Black; John Harsh; Claudio Bassetti; Harald Schrader; Seiji Nishino
Journal:  Arch Neurol       Date:  2002-10

5.  Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke.

Authors:  T E Scammell; S Nishino; E Mignot; C B Saper
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

6.  CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.

Authors:  Takashi Kanbayashi; Yuichi Inoue; Shigeru Chiba; Rika Aizawa; Yasushi Saito; Haruko Tsukamoto; Yukiharu Fujii; Seiji Nishino; Tetsuo Shimizu
Journal:  J Sleep Res       Date:  2002-03       Impact factor: 3.981

7.  Hypocretin-1 (orexin-A) concentrations in cerebrospinal fluid are low in patients with Guillain-Barré syndrome.

Authors:  Takashi Kanbayashi; Hideaki Ishiguro; Rika Aizawa; Yasushi Saito; Yuriko Ogawa; Masahito Abe; Kouichi Hirota; Seiji Nishino; Tetsuo Shimizu
Journal:  Psychiatry Clin Neurosci       Date:  2002-06       Impact factor: 5.188

8.  A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid.

Authors:  Hiroaki Kubota; Takashi Kanbayashi; Yuzo Tanabe; Jun-ichi Takanashi; Yoichi Kohno
Journal:  J Child Neurol       Date:  2002-07       Impact factor: 1.987

Review 9.  Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation.

Authors:  Carsten T Beuckmann; Masashi Yanagisawa
Journal:  J Mol Med (Berl)       Date:  2002-04-05       Impact factor: 4.599

10.  Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions.

Authors:  Takashi Kato; Takashi Kanbayashi; Kanji Yamamoto; Takeshi Nakano; Tetsuo Shimizu; Takao Hashimoto; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2003-08       Impact factor: 1.271
View more
  11 in total

1.  Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody.

Authors:  Toru Baba; Ichiro Nakashima; Takashi Kanbayashi; Masatoshi Konno; Toshiyuki Takahashi; Kazuo Fujihara; Tatsuro Misu; Atsushi Takeda; Yusei Shiga; Hiromasa Ogawa; Yasuto Itoyama
Journal:  J Neurol       Date:  2009-03-05       Impact factor: 4.849

2.  Neurosarcoidosis presenting as spontaneously remitting hypersomnia.

Authors:  Yoshihiko Nakazato; Sayaka Kondo; Aya Ohkuma; Yasuo Ito; Naotoshi Tamura; Nobuo Araki
Journal:  J Neurol       Date:  2009-07-16       Impact factor: 4.849

3.  Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event.

Authors:  Recai Türkoğlu; Gülçin Benbir; Selen Özyurt; Erdil Arsoy; Ece Akbayır; Selin Turan; Derya Karadeniz; Vuslat Yılmaz; Mehmet Gencer; Erdem Tüzün
Journal:  Int Ophthalmol       Date:  2019-08-20       Impact factor: 2.031

Review 4.  Sleep disorders in multiple sclerosis. Review.

Authors:  Christian Veauthier
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

Review 5.  Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation.

Authors:  Kevin G Burfeind; Vijayshree Yadav; Daniel L Marks
Journal:  Curr Neurol Neurosci Rep       Date:  2016-11       Impact factor: 5.081

Review 6.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

Review 7.  Hypocretin/orexin and narcolepsy: new basic and clinical insights.

Authors:  S Nishino; M Okuro; N Kotorii; E Anegawa; Y Ishimaru; M Matsumura; T Kanbayashi
Journal:  Acta Physiol (Oxf)       Date:  2009-06-25       Impact factor: 6.311

Review 8.  Is there a link between inflammation and fatigue in multiple sclerosis?

Authors:  Moussa A Chalah; Samar S Ayache
Journal:  J Inflamm Res       Date:  2018-06-07

Review 9.  Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Int J Mol Sci       Date:  2018-04-16       Impact factor: 5.923

Review 10.  Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity.

Authors:  Maria P Mogavero; Alessandro Silvani; Lourdes M DelRosso; Michele Salemi; Raffaele Ferri
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.